ncRNA basic information
ncRNA ID:
MI0000452/MI0000453
ncRNA Database:
miRBase
ncRNA Name:
miR-135a
ncRNA Type:
miRNA
ncRNA Expression:
up-regulated
ncRNA Method:
qRT-PCR
ncRNA Target Gene:
HIF1AN
ncRNA Pathway:
NA
Evidence (ncRNA-drug):
validated
drug basic information
Drug ID:
DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281)
Drug Name:
Paclitaxel
Drug Method:
In this study, we utilized microRNA (miRNA) arrays to screen for differentially expressed miRNAs in paclitaxel-resistant cell lines established in vitro. We observed concordant upregulation of miR-135a in paclitaxel-resistant cell lines representing three human malignancies. Subsequently, the role of miRNA-135a was evaluated in an in vivo model of paclitaxel resistance. In this model, mice were inoculated subcutaneously with a non-small cell lung carcinoma cell line and treated with paclitaxel for a prolonged period. In paclitaxel-resistant cell lines, established either in vitro or in vivo, blockage of miR-135a sensitized resistant cell lines to paclitaxel-induced cell death. We further demonstrated a correlation between paclitaxel response and miR-135a expression in paclitaxel-resistant subclones that were established in vivo. The paclitaxel-resistant phenotype of these subclones was maintained upon retransplantation in new mice, as shown by decreased tumor response upon paclitaxel treatment compared with controls. Upregulation of miR-135a was associated with reduced expression of the adenomatous polyposis coli gene (APC). APC knockdown increased paclitaxel resistance in parental cell lines.
Drug Response:
resistant
Cancer basic information
Cancer:
breast cancer
Tissue/Cell:
cell line (A549,PC-14,PC-14/TXT,MCF-7,MCF-7TAX,PC-3,PC-3TXR,SKOV-3,SKOV-3TR,MES-SADX5)
Other information
Title:
miR-135a contributes to paclitaxel resistance in tumor cells both in vitro and in vivo.
Journal:
Oncogene
Published:
2011
PubMed ID:
21552288